Clinical characteristics and prognosis of pancreatitis associated with immune checkpoint inhibitors.

IF 2.8 3区医学 Q2 ONCOLOGY

Clinical & Translational Oncology Pub Date : 2025-01-01 Epub Date: 2024-07-12 DOI:10.1007/s12094-024-03573-7

Junzi Zhang, Xianzhuo Jiang, Ning Liu, Zhaoxue Qi, Xuguang Mi, Yanqiu Fang, Wenqi Zhang, Zhen Yang, Wenjie Ou, Xiuying Lin, Junjie Hou

{"title":"Clinical characteristics and prognosis of pancreatitis associated with immune checkpoint inhibitors.","authors":"Junzi Zhang, Xianzhuo Jiang, Ning Liu, Zhaoxue Qi, Xuguang Mi, Yanqiu Fang, Wenqi Zhang, Zhen Yang, Wenjie Ou, Xiuying Lin, Junjie Hou","doi":"10.1007/s12094-024-03573-7","DOIUrl":null,"url":null,"abstract":"Background and objective: Immune checkpoint inhibitors (ICIs) have shown remarkable efficacy against various cancers in clinical practice. However, ICIs can cause immune checkpoint inhibitor-associated pancreatic injury, often leading to drug withdrawal, and then patients must go to specialized treatment. The patients, their primary tumors are sensitive to ICIs therapy, may experience treatment delays due to such adverse reactions. Therefore, there is a need for systematic clinical researches on immune-related pancreatic toxicity to provide a clinical basis for its prevention and treatment.Methods: This study involved the collection of data from patients treated with ICIs and addressed pancreatic injury with preemptive treatment before continuing ICIs therapy. Then, we also statistically analyzed the incidence of pancreatic injury in patients with different courses and combined treatment, and the success rate of rechallenge treatment.Results: The study included 62 patients, with 33.9% (21/62) experiencing varying degrees of pancreatic injury. Patients with pancreatic injury, 10 cases evolved into pancreatitis, representing 47.6% (10/21) in the pancreatic injury subgroup and 16.1% (10/62) of the total patient cohort. Preemptive treatment was administered to 47.6% (10/21) of patients with pancreatitis, the effective rate was 100%. Among these patients, 70% (7/10) underwent successful rechallenge with ICIs. The occurrence of pancreatic injury was positively correlated with the treatment duration (P < 0.05) but showed no significant correlation with combination therapies (P > 0.05).Conclusion: The likelihood of pancreatic injury increased with longer treatment durations with ICIs; no significant association was found between the incidence of ICIs-related pancreatic damage and combination therapies. Preemptive treatment for immune-related pancreatitis is feasible, allowing some patients to successfully undergo rechallenge with ICIs therapy.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"333-339"},"PeriodicalIF":2.8000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12094-024-03573-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/12 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objective: Immune checkpoint inhibitors (ICIs) have shown remarkable efficacy against various cancers in clinical practice. However, ICIs can cause immune checkpoint inhibitor-associated pancreatic injury, often leading to drug withdrawal, and then patients must go to specialized treatment. The patients, their primary tumors are sensitive to ICIs therapy, may experience treatment delays due to such adverse reactions. Therefore, there is a need for systematic clinical researches on immune-related pancreatic toxicity to provide a clinical basis for its prevention and treatment.

Methods: This study involved the collection of data from patients treated with ICIs and addressed pancreatic injury with preemptive treatment before continuing ICIs therapy. Then, we also statistically analyzed the incidence of pancreatic injury in patients with different courses and combined treatment, and the success rate of rechallenge treatment.

Results: The study included 62 patients, with 33.9% (21/62) experiencing varying degrees of pancreatic injury. Patients with pancreatic injury, 10 cases evolved into pancreatitis, representing 47.6% (10/21) in the pancreatic injury subgroup and 16.1% (10/62) of the total patient cohort. Preemptive treatment was administered to 47.6% (10/21) of patients with pancreatitis, the effective rate was 100%. Among these patients, 70% (7/10) underwent successful rechallenge with ICIs. The occurrence of pancreatic injury was positively correlated with the treatment duration (P < 0.05) but showed no significant correlation with combination therapies (P > 0.05).

Conclusion: The likelihood of pancreatic injury increased with longer treatment durations with ICIs; no significant association was found between the incidence of ICIs-related pancreatic damage and combination therapies. Preemptive treatment for immune-related pancreatitis is feasible, allowing some patients to successfully undergo rechallenge with ICIs therapy.

查看原文本刊更多论文

与免疫检查点抑制剂相关的胰腺炎的临床特征和预后。

背景和目的：在临床实践中，免疫检查点抑制剂（ICIs）对各种癌症具有显著疗效。然而，ICIs 可导致免疫检查点抑制剂相关性胰腺损伤，往往会导致停药，然后患者必须接受专门治疗。原发肿瘤对 ICIs 治疗敏感的患者可能会因此类不良反应而延误治疗。因此，有必要对免疫相关的胰腺毒性进行系统的临床研究，为其预防和治疗提供临床依据：本研究收集了接受 ICIs 治疗的患者数据，并在继续 ICIs 治疗前对胰腺损伤进行先期治疗。然后，我们还统计分析了不同疗程和联合治疗患者的胰腺损伤发生率，以及再挑战治疗的成功率：研究共纳入 62 例患者，其中 33.9%（21/62）的患者出现不同程度的胰腺损伤。胰腺损伤患者中有 10 例演变为胰腺炎，占胰腺损伤亚组的 47.6%（10/21），占患者总数的 16.1%（10/62）。47.6%（10/21）的胰腺炎患者接受了先期治疗，有效率为 100%。在这些患者中，70%（7/10）成功接受了 ICIs 再挑战。胰腺损伤的发生与治疗时间呈正相关（P 0.05）：结论：胰腺损伤的可能性随着 ICIs 治疗时间的延长而增加；ICIs 相关胰腺损伤的发生率与联合疗法之间未发现显著关联。对免疫相关性胰腺炎进行先期治疗是可行的，一些患者可以成功接受 ICIs 治疗的再挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical & Translational Oncology 医学-肿瘤学

CiteScore

6.20

自引率

2.90%

发文量

240

审稿时长

1 months

期刊介绍： Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.